Regentis Biomaterials Ltd. (NYSE American: RGNT), a regenerative medicine company focused on innovative tissue repair solutions, reported significant interest and engagement from orthopedic surgeons, physicians, and cartilage repair specialists at the 8th International Cartilage Regeneration & Joint Preservation Society (ICRS) Summit, held October 8-10 in Porto, Portugal. The discussions centered on GelrinC®, the company’s CE Mark-approved, cell-free hydrogel implant designed to regenerate damaged knee cartilage through a single procedure lasting approximately 10 minutes. This news matters because it signals growing clinical momentum for a novel treatment that could address a substantial unmet need in orthopedic care.
In a Phase II study, GelrinC demonstrated approximately 100% greater improvement in overall Knee Injury and Osteoarthritis Outcome Score (KOOS) scores compared with historical microfracture controls at two years. Subsequent MRI analyses showed results consistent with durable, native-like cartilage regeneration. These findings are particularly important because they suggest GelrinC may offer a more effective and lasting solution than current standards, potentially reducing the need for repeated surgeries and improving long-term patient outcomes.
Regentis is working to translate physician interest into broader clinical adoption through its expanding European Centers of Excellence while advancing its ongoing U.S. Food and Drug Administration pivotal trial. The company’s efforts are supported by its Gelrin platform technology, based on synchronized, degradable hydrogel implants that regenerate damaged or diseased tissue, including inflamed cartilage and bone. GelrinC is a cell-free, off-the-shelf hydrogel that is eroded and resorbed in the knee, allowing surrounding cells to regenerate cartilage in a controlled and synchronous process. This approach aims to address a market of approximately 470,000 cases for cartilage knee repair annually in the U.S. where no off-the-shelf treatment is available.
The strong surgeon interest at the ICRS Summit underscores the potential for GelrinC to become a leading option in cartilage repair, which could significantly impact the orthopedic industry by providing a minimally invasive, single-procedure solution. For readers, this development may herald new hope for patients suffering from knee cartilage damage, potentially offering faster recovery and improved quality of life. As Regentis continues to gather clinical evidence and expand its reach, the adoption of GelrinC could reshape treatment paradigms and drive growth in the regenerative medicine sector.
For more information on Regentis Biomaterials, visit their client page. The full press release can be accessed at https://ibn.fm/hcEu4. InvestorWire, a specialized communications platform, distributed this announcement as part of its press release syndication services. InvestorWire is one of 75+ brands within the Dynamic Brand Portfolio @ IBN, which provides editorial syndication to 5,000+ outlets and social media distribution to millions of followers. For full terms, see the InvestorWire disclaimer.
